Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00094107 | Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma | completed | Phase 2 | 32 | PfizerINDUSTRY | 2 | Jun 26, 2012 | clinicaltrials |
| NCT00077532 | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 179 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jun 22, 2012 | clinicaltrials |
| NCT00080353 | Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00295958 | LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 26 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00846833 | Haploidentical NK Cell Infusion in Malignant Melanoma | completed | Phase 1 / Phase 2 | 12 | Seoul National University HospitalOTHER | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00254579 | Study of CP-675,206 in Refractory Melanoma | completed | Phase 2 | 251 | AstraZenecaINDUSTRY | 9 | Jun 7, 2012 | clinicaltrials |
| NCT00281541 | A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma | completed | Phase 2 | 29 | Astellas Pharma IncINDUSTRY | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00086489 | CP-675,206 In Patients With Advanced Melanoma | completed | Phase 2 | 118 | AstraZenecaINDUSTRY | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00412425 | Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting | completed | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2012 | clinicaltrials |
| NCT00483301 | A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma | completed | Phase 2 | 34 | Mt. Sinai Medical Center, MiamiOTHER | 1 | May 3, 2012 | clinicaltrials |
| NCT00616564 | Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma | completed | Phase 2 | 36 | Mt. Sinai Medical Center, MiamiOTHER | 1 | May 3, 2012 | clinicaltrials |
| NCT00035165 | EPO906 Therapy in Patients With Advanced Melanoma | completed | Phase 2 | 51 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 25, 2012 | clinicaltrials |
| NCT01048554 | Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System(MEL0107) | completed | Phase 2 | 34 | Mt. Sinai Medical Center, MiamiOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT00316901 | Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | completed | Phase 2 | 70 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 15, 2012 | clinicaltrials |
| NCT00002860 | SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 77 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 13, 2012 | clinicaltrials |
| NCT00006233 | Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00006385 | Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 1 | Nov 8, 2011 | clinicaltrials |
| NCT00204581 | Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases | completed | Phase 2 | 51 | University Hospital TuebingenOTHER | 1 | Aug 19, 2011 | clinicaltrials |
| NCT00003646 | Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 2 | 78 | VicalINDUSTRY | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00044356 | Phase II Trial of Allovectin-7® for Metastatic Melanoma | completed | Phase 2 | 133 | VicalINDUSTRY | 1 | Jul 7, 2011 | clinicaltrials |
| NCT00658437 | CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy | completed | Phase 2 | 31 | Cytavis Biopharma GmbHINDUSTRY | 1 | Jun 8, 2011 | clinicaltrials |
| NCT00602199 | ABT-510 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 42 | Mayo ClinicOTHER | 0 | May 16, 2011 | clinicaltrials |
| NCT00003091 | High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma | completed | Phase 2 | 40 | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 12, 2011 | clinicaltrials |
| NCT00033228 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 / Phase 2 | 19 | Mannkind CorporationINDUSTRY | 1 | May 12, 2011 | clinicaltrials |
| NCT00261404 | TNFerade™ Biologic Plus Radiation for Metastatic Melanoma | completed | Phase 2 | — | GenVecINDUSTRY | 1 | May 12, 2011 | clinicaltrials |
| NCT00002733 | Biological Therapy in Treating Patients With Metastatic Cancer | completed | Phase 2 | 30 | Hoag Memorial Hospital PresbyterianOTHER | 1 | May 11, 2011 | clinicaltrials |
| NCT00050102 | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma | completed | Phase 2 | — | Bristol-Myers SquibbINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00881049 | Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma | completed | Phase 2 | 1 | Peking UniversityOTHER | 1 | Jan 17, 2011 | clinicaltrials |
| NCT00623402 | Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma(SoraPeg) | completed | Phase 2 | 55 | University Hospital Schleswig-HolsteinOTHER | 1 | Jan 12, 2011 | clinicaltrials |
| NCT00651703 | Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients | completed | Phase 2 | 21 | Cytos Biotechnology AGINDUSTRY | 1 | Nov 15, 2010 | clinicaltrials |
| NCT00327600 | Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 68 | AmpliMed CorporationINDUSTRY | 1 | Sep 15, 2010 | clinicaltrials |
| NCT00609011 | Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma | completed | Phase 1 / Phase 2 | 22 | Myrexis Inc.INDUSTRY | 1 | Aug 23, 2010 | clinicaltrials |
| NCT00002786 | Biological Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | May 10, 2010 | clinicaltrials |
| NCT00197912 | Dendritic Cell Based Therapy of Malignant Melanoma | completed | Phase 1 / Phase 2 | 25 | Herlev HospitalOTHER | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00289640 | Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 210 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 2, 2010 | clinicaltrials |
| NCT00794235 | Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine | completed | Phase 2 | 12 | University of ZurichOTHER | 1 | Jan 8, 2010 | clinicaltrials |
| NCT00116597 | Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 2, 2009 | clinicaltrials |
| NCT00243529 | Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients | completed | Phase 1 / Phase 2 | 64 | Radboud University Medical CenterOTHER | 1 | Sep 29, 2009 | clinicaltrials |
| NCT00911443 | Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma | completed | Phase 2 | 488 | sigma-tau i.f.r. S.p.A.INDUSTRY | 8 | Jul 9, 2009 | clinicaltrials |
| NCT00308607 | Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma | completed | Phase 2 | 27 | University of TurkuOTHER | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00243594 | Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection | completed | Phase 1 / Phase 2 | 40 | Radboud University Medical CenterOTHER | 1 | Feb 19, 2009 | clinicaltrials |
| NCT00847106 | Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients | completed | Phase 1 / Phase 2 | 15 | Radboud University Medical CenterOTHER | 0 | Feb 19, 2009 | clinicaltrials |
| NCT00189332 | Use of 852A in Metastatic Cutaneous Melanoma. | completed | Phase 2 | 28 | PfizerINDUSTRY | 3 | Oct 27, 2008 | clinicaltrials |
| NCT00099970 | Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy | completed | Phase 2 | 40 | PDL BioPharma, Inc.INDUSTRY | 1 | Aug 5, 2008 | clinicaltrials |
| NCT00001685 | Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase | completed | Phase 2 | 114 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001705 | Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence | completed | Phase 2 | 141 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00066196 | Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma | completed | Phase 2 | 110 | MedImmune LLCINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00306514 | Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients | completed | Phase 1 / Phase 2 | — | Cytos Biotechnology AGINDUSTRY | 1 | Sep 20, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Jun 26, 2012source: clinicaltrials